Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURVA+: Durvalumab with Chemotherapy in Advanced Solid Tumors
NCT03907475Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2019
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in solid tumor, sponsored by National Cancer Institute. Started Jul 2019; status: recruiting.
02
Drugs
durvalumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03907475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03907475.